T-cell immunoglobulin and mucin domain-containing-3 (TIM-3) has emerged as a promising therapeutic target in OC due to its prevalent expression in tumor tissues [8] and its strong correlation with the poor prognosis in HGSOC patients [9]. Here, HAVCR2 is linked to neoplasm.